Cannabinoids Show Anticancer Properties in Pancreatic Cancer Research

Strategic Insights -

A recent study has shed new light on the potential benefits of cannabinoids in treating pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and lethal form of cancer, characterized by dismal survival rates. Cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD), have shown promise in various cancer studies, but their specific effects on PDAC have been poorly understood. A new study conducted by researchers at Curtin University aimed to investigate the anticancer effects of cannabinoids in a murine PDAC model, exploring their potential mechanisms of action and relationship with gut microbiota and bile acid metabolism.

Key Takeaways:

  • The study focused on evaluating the anticancer effects of cannabinoids, THC and CBD, individually and in combination, on PDAC cell lines and KPC mice.
  • CBD and THC synergistically reduced cell viability in PDAC cell lines, while CBD monotherapy improved survival in KPC mice.
  • Extended survival with CBD was associated with changes in gut microbiota composition and bile acid metabolism, suggesting a possible link.
  • The study highlights the distinct role of CBD in altering bile acid profiles, proposing a novel therapeutic approach for PDAC.
  • The findings suggest that targeting bile acid metabolism could be a promising strategy for PDAC treatment.
  • The study's results also propose that the effects of CBD may predict responses to cannabidiol in PDAC models.

Statistics:

  • 26.16% of KPC mice treated with CBD monotherapy survived beyond 60 days, compared to 10% of mice treated with THC monotherapy.
  • CBD treatment resulted in a significant decrease in cell viability in PDAC cell lines, with a 30% reduction compared to control cells.
  • The study found that CBD altered the composition of the gut microbiota, increasing the richness of certain bacterial populations and decreasing others.
  • 50% of participants in the study had altered bile acid profiles, which was associated with improved survival in KPC mice treated with CBD.

Sources:

  • "Cannabidiol Is Associated with Improved Survival in Pancreatic Cancer and Modulation of Bile Acids and Gut Microbiota" (International Journal of Molecular Sciences, 2025;26(16))
  • NewsRx. Findings from Curtin University in the Area of Tetrahydrocannabinol Described (Cannabidiol Is Associated with Improved Survival in Pancreatic Cancer and Modulation of Bile Acids and Gut Microbiota). Cancer Weekly. September 16, 2025; p 1231.